Dyadic International, Inc.

[Not Yet Scheduled]
We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression platform to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and lower cost to patients and the healthcare system. We believe that C1 will become an alternative protein expression host cells (other than CHO, and E.coli) for the high yield/low cost production of mAbs, bi-specific and multi-specific antibodies, Fc-fusion and other types of therapeutic antibodies, antibody fragments, virus like particles, and vaccines.
Ticker:
DYAI
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
1979
Main Therapeutic Focus:
Lead Product in Development:
DYAI-100
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Dyadic International, Inc